Journal
BIOCHEMICAL PHARMACOLOGY
Volume 198, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2022.114954
Keywords
Extracellular vesicles; Skeletal muscle atrophy
Categories
Funding
- National Natural Science Foundation of China [82072160, 32130060, 92068112, 81901933]
- Major Natural Science Research Projects in Universities of Jiangsu Province [20KJA310012]
- Natural Science Foundation of Jiangsu Province [BK20202013, BK20201209]
- QingLan Project in Jiangsu Universities
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Nantong Science and Technology Program [JCZ19066]
Ask authors/readers for more resources
Pathophysiological changes of skeletal muscle can cause muscle atrophy and dysfunction, greatly affecting quality of life. Extracellular vesicles (EVs) are involved in the pathophysiological processes of skeletal muscle. EVs play a role in skeletal muscle growth, regeneration, and atrophy by delivering bioactive molecules. EVs have potential as biomarkers and therapeutic carriers for skeletal muscle diseases.
Pathophysiological changes of skeletal muscle occur in a variety of chronic diseases, leading to muscle atrophy and dysfunction, which greatly affect the quality of life. Despite decades of research, the pathogenesis of muscle atrophy remains poorly understood. Extracellular vesicles (EVs) have recently been demonstrated to be associ-ated with the pathophysiological process of skeletal muscle. EVs are membrane-encapsulated nanovesicles secreted by multiple organisms. They can deliver bioactive molecules (proteins, lipids, DNA and RNA, etc.) to the target cells, affecting the biological function of the target cells. The delivery of bioactive molecules by EVs has become an important mode of intercellular communication. In this review, we discuss the biogenesis, classifi-cation, extraction and identification of EVs, clarify the role of bioactive molecules in EVs in skeletal muscle growth, regeneration and atrophy and explore the potential of EVs as a novel biomarker and therapeutic carrier for skeletal muscle diseases. The current review aims to highlight the emerging evidence linking EVs to the pathophysiological mechanism of skeletal muscle atrophy and to discuss the perspectives of EVs as a treatment for skeletal muscle atrophy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available